Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 5/20 | 0.40 |
| ▸ | CCND1 | P24385 | 3/20 | 0.40 |
| ▸ | FLT4 | P35916 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 3/20 | 0.39 |
| ▸ | MARK3 | P27448 | 5/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | CCND2 | P30279 | 2/20 | 0.36 |
| ▸ | CCND3 | P30281 | 2/20 | 0.36 |
| ▸ | MARK4 | Q96L34 | 3/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1285558 | 0.87 | CDK4 (0.45) | CDK4CCND1FLT4KDRAURKA | |
| SCHEMBL1284750 | 0.86 | MAP3K5 (0.46) | CDK4AURKAPDGFRBEGFR | |
| SCHEMBL1284702 | 0.85 | SYK (0.42) | CDK4CCND1FLT4KDRAURKA | |
| SCHEMBL1285070 | 0.85 | CDK4 (0.45) | CDK4CCND1FLT4KDRAURKA | |
| SCHEMBL1284416 | 0.85 | JAK3 (0.49) | FLT4KDRCDK2DYRK1A | |
| SCHEMBL1284597 | 0.84 | SYK (0.46) | CDK4CCND1AURKACCND3CCNA2 | |
| SCHEMBL1285497 | 0.84 | MAP3K5 (0.46) | CDK4AURKAPDGFRBEGFR | |
| SCHEMBL1284875 | 0.84 | TBK1 (0.42) | CDK4FLT4KDRAURKAMARK3 | |
| SCHEMBL1284997 | 0.83 | TBK1 (0.47) | CDK4FLT4KDRAURKAMARK3 | |
| SCHEMBL1284716 | 0.83 | AURKA (0.38) | CDK4FLT4KDRAURKAMARK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | claimed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MARK3, MAPK8, CDK8 | CDK4 85/4885CCND1 574/4885FLT4 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.